Tamoxifen in patients with advanced epithelial ovarian cancer.
Tamoxifen was administered to 30 patients with persistent or recurrent epithelial ovarian cancer following initial plantinum-based chemotherapy. Two complete remissions (lasting 41 months and 12 months, respectively) were documented (6.6%), while 10 patients (33.3%) had stabilization of disease for a mean duration of 11.5 months. Tamoxifen was not associated with any significant toxicity and is a reasonable therapeutic option for patients with persistent or recurrent ovarian cancer, although it is only associated with modest activity. This paper reviews our experience with tamoxifen and summarizes the world literature.
Van Der Velden
J.
J
Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia.
Gitsch
G.
G
Wain
G.V.
GV
Friedlander
M.L.
ML
Hacker
N.F.
NF